vs
ASP Isotopes Inc.（ASPI）与Assertio Holdings, Inc.（ASRT）财务数据对比。点击上方公司名可切换其他公司
ASP Isotopes Inc.的季度营收约是Assertio Holdings, Inc.的1.2倍（$16.7M vs $13.5M），ASP Isotopes Inc.同比增速更快（1295.7% vs -57.9%）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
Assertio Therapeutics是一家美国专业制药企业，主要聚焦神经病学、疼痛以及中枢神经系统疾病领域的产品销售与推广。公司前身Depomed成立于1995年，总部位于加利福尼亚州纽瓦克，拥有多款获美国FDA批准的产品，目前在纳斯达克上市。
ASPI vs ASRT — 直观对比
营收规模更大
ASPI
是对方的1.2倍
$13.5M
营收增速更快
ASPI
高出1353.6%
-57.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $13.5M |
| 净利润 | — | — |
| 毛利率 | 12.5% | — |
| 营业利润率 | — | -86.7% |
| 净利率 | — | — |
| 营收同比 | 1295.7% | -57.9% |
| 净利润同比 | -586.8% | — |
| 每股收益（稀释后） | — | $-4.54 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPIASRT
| Q4 25 | $16.7M | $13.5M | ||
| Q3 25 | $4.9M | $49.5M | ||
| Q2 25 | — | $29.2M | ||
| Q1 25 | — | $26.5M | ||
| Q4 24 | — | $32.2M | ||
| Q3 24 | — | $29.2M | ||
| Q2 24 | — | $31.1M | ||
| Q1 24 | — | $32.4M |
净利润ASPIASRT
| Q4 25 | — | — | ||
| Q3 25 | $-12.9M | $11.4M | ||
| Q2 25 | — | $-16.4M | ||
| Q1 25 | — | $-13.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-2.9M | ||
| Q2 24 | — | $-3.7M | ||
| Q1 24 | — | $-4.5M |
毛利率ASPIASRT
| Q4 25 | 12.5% | — | ||
| Q3 25 | 8.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率ASPIASRT
| Q4 25 | — | -86.7% | ||
| Q3 25 | -306.1% | 23.2% | ||
| Q2 25 | — | -27.5% | ||
| Q1 25 | — | -50.0% | ||
| Q4 24 | — | -41.9% | ||
| Q3 24 | — | -10.4% | ||
| Q2 24 | — | -11.6% | ||
| Q1 24 | — | -13.4% |
净利率ASPIASRT
| Q4 25 | — | — | ||
| Q3 25 | -263.7% | 23.1% | ||
| Q2 25 | — | -56.0% | ||
| Q1 25 | — | -51.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -10.0% | ||
| Q2 24 | — | -11.8% | ||
| Q1 24 | — | -13.9% |
每股收益（稀释后）ASPIASRT
| Q4 25 | — | $-4.54 | ||
| Q3 25 | $-0.15 | $0.11 | ||
| Q2 25 | — | $-0.17 | ||
| Q1 25 | — | $-0.14 | ||
| Q4 24 | — | $-3.28 | ||
| Q3 24 | — | $-0.03 | ||
| Q2 24 | — | $-0.04 | ||
| Q1 24 | — | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $63.4M |
| 总债务越低越好 | $14.4M | — |
| 股东权益账面价值 | $204.2M | $94.0M |
| 总资产 | $498.0M | $267.0M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资ASPIASRT
| Q4 25 | $333.3M | $63.4M | ||
| Q3 25 | $113.9M | $93.4M | ||
| Q2 25 | — | $98.2M | ||
| Q1 25 | — | $87.3M | ||
| Q4 24 | — | $100.1M | ||
| Q3 24 | — | $88.6M | ||
| Q2 24 | — | $88.4M | ||
| Q1 24 | — | $80.7M |
总债务ASPIASRT
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $38.6M |
股东权益ASPIASRT
| Q4 25 | $204.2M | $94.0M | ||
| Q3 25 | $74.1M | $105.8M | ||
| Q2 25 | — | $93.3M | ||
| Q1 25 | — | $108.5M | ||
| Q4 24 | — | $121.1M | ||
| Q3 24 | — | $130.5M | ||
| Q2 24 | — | $132.2M | ||
| Q1 24 | — | $134.5M |
总资产ASPIASRT
| Q4 25 | $498.0M | $267.0M | ||
| Q3 25 | $225.9M | $319.8M | ||
| Q2 25 | — | $273.8M | ||
| Q1 25 | — | $286.4M | ||
| Q4 24 | — | $284.7M | ||
| Q3 24 | — | $276.0M | ||
| Q2 24 | — | $279.4M | ||
| Q1 24 | — | $282.0M |
负债/权益比ASPIASRT
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.29× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-30.0M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | — |
| 自由现金流率自由现金流/营收 | -284.7% | — |
| 资本支出强度资本支出/营收 | 57.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASPIASRT
| Q4 25 | $-37.8M | $-30.0M | ||
| Q3 25 | $-8.9M | $-4.8M | ||
| Q2 25 | — | $19.1M | ||
| Q1 25 | — | $-12.5M | ||
| Q4 24 | — | $11.5M | ||
| Q3 24 | — | $-35.0K | ||
| Q2 24 | — | $7.4M | ||
| Q1 24 | — | $7.5M |
自由现金流ASPIASRT
| Q4 25 | $-47.4M | — | ||
| Q3 25 | $-12.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率ASPIASRT
| Q4 25 | -284.7% | — | ||
| Q3 25 | -245.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度ASPIASRT
| Q4 25 | 57.9% | — | ||
| Q3 25 | 64.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率ASPIASRT
| Q4 25 | — | — | ||
| Q3 25 | — | -0.42× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASPI
暂无分部数据
ASRT
| Products | $12.8M | 95% |
| Other | $719.0K | 5% |
